Search

Your search keyword '"Bodrogi, Istvan"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Bodrogi, Istvan" Remove constraint Author: "Bodrogi, Istvan"
35 results on '"Bodrogi, Istvan"'

Search Results

2. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

3. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

4. The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred

6. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II

7. Younger age-at-diagnosis for familial malignant testicular germ cell tumor

8. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

9. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

10. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

12. The Y deletion gr/gr and susceptibility to testicular germ cell tumor

13. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

14. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci

17. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci

18. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

20. Analysis of the DNDI gene in men with sporadic and familial testicular germ cell tumors

21. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial

22. PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

23. Side-effect analysis of sunitinib (S) in patients treated with metastatic renal cell cancer (mRCC): Single center experience in the National Institute of Oncology, Hungary—Influence of dose reduction/modification and application schedule on the efficacy of S.

24. Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.

25. Prognostic factors for survival in the phase III TROPIC trial.

26. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

27. Analysis of theDND1 gene in men with sporadic and familial testicular germ cell tumors

28. Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

29. Corrigendum to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I” [Eur Urol 2008;53:478–96] and to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part II” [Eur Urol 2008;53:497–513]

30. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

31. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

32. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci

34. Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors.

35. Expression of HER-2/neu in testicular tumors.

Catalog

Books, media, physical & digital resources